Sozialstiftung Bamberg
- Address
- Buger Strasse 80, Berg, 96049 Bamberg, Germany
Advanced ER‑positive/HER2‑negative Breast Cancer Studies
The Sozialstiftung Bamberg clinic is conducting research focused on estrogen receptor‑positive, HER2‑negative advanced breast cancer, aiming to improve survival outcomes and understand treatment resistance.
- Evaluation of new endocrine therapies versus standard treatments
- Analysis of molecular markers such as ESR1 mutations
- Assessment of progression‑free and overall survival metrics
These efforts support patients by exploring more effective options and refining prognostic expectations.
Targeted CDK4/6 and Novel Oral Agents
Investigators are testing the combination of a CDK4/6 inhibitor with novel oral agents like giredestrant to overcome resistance in the first‑line therapeutic setting.
- Comparative efficacy of giredestrant versus fulvestrant
- Impact on progression‑free survival in ESR1‑mutated subgroups
- Safety profiling of combined endocrine and CDK4/6 blockade
The research aims to broaden treatment choices for women with advanced disease while maintaining quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sozialstiftung Bamberg
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS | Institut fuer Frauengesundheit GmbH | Phase III | Recruiting | Oct 2022 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fulvestrant | 2 | Unknown | 2022-10-13 | 2024-01-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.